(Encelimab)Biosimilar Reference Antibody-GS40224 新品

货号：GS40224

Encelimab (development code TSR-033) is an investigational, humanized immunoglobulin G4 (IgG4) monoclonal antibody developed for cancer immunotherapy. It functions as a selective lymphocyte activation gene-3 (LAG-3) inhibitor. By specifically and potently binding to the LAG-3 receptor expressed on the surface of immune cells (primarily T cells), encelimab blocks its interaction with major histocompatibility complex class II (MHC-II) molecules and other potential ligands. This blockade releases the inhibitory "brake" that LAG-3 imposes on T-cell activation, proliferation, and effector function, thereby aiming to restore and enhance the anti-tumor immune response, particularly in T cells that are exhausted or dysfunctional.